Eli Lilly Medicare Obesity: $15B Market Boom Builds
Can Medicare coverage and faster FDA plant approvals turn Eli Lilly’s obesity franchise into an even bigger profit machine? Maik Kemper Editor in Chief From my perspective, both…
Eli Lilly Record at $1 Trillion as GLP-1 Boom Lifts LLY
Can Eli Lilly’s record run keep defying gravity as GLP-1 dominance and billion-dollar dealmaking reshape Big Pharma? Maik Kemper Editor in Chief Lilly’s AI-infused commercial engine is now…
Eli Lilly Jaypirca Approval +6.8% as CHMP Backs CLL Use
Can Eli Lilly Jaypirca Approval turn a regulatory win into a lasting oncology growth engine for investors? Maik Kemper Editor in Chief The CHMP’s positive opinion reflects compelling…
Eli Lilly Acquisition Signals Pain Drug Boom Beyond GLP-1
Can Eli Lilly’s latest deal prove the company is more than a one-theme GLP-1 growth story? Maik Kemper Editor in Chief The company was focused on four main…
Eli Lilly Orforglipron Powers $19.8B Surge as Risks Rise
Can Eli Lilly Orforglipron justify Lilly’s trillion-dollar valuation as GLP-1 growth accelerates and pricing pressure starts to bite? Maik Kemper Editor in Chief Eli Lilly Orforglipron’s oral profile,…
Eli Lilly LillyDirect +5.4% as Weight Watchers Expands Access
Can Eli Lilly LillyDirect turn obesity drugs into a full-service care platform that rivals cannot easily copy? Maik Kemper Editor in Chief LillyDirect is becoming the de facto…
Eli Lilly Zepbound Coverage +5.2% as CVS Restores Access
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war? Maik Kemper Editor in Chief “Collaboration with pharmaceutical companies…
Eli Lilly Acquisition $3.8B Push Opens Vaccine Growth Lane
Can Eli Lilly turn obesity cash into its next blockbuster by spending $3.83 billion on vaccines? Maik Kemper Editor in Chief The deals reflect a deliberate strategy to…
Eli Lilly Earnings +56%: Can the GLP‑1 Boom Last?
Are Eli Lilly Earnings riding a temporary GLP‑1 sugar high, or is this the start of a durable new profit cycle? Maik Kemper Editor in Chief 2026 is…
Eli Lilly Earnings Soar 156% as GLP‑1 Boom Lifts Outlook
Are Eli Lilly earnings finally proving that the GLP‑1 obesity boom can justify today’s sky‑high valuation? Maik Kemper Editor in Chief 2026 is off to a strong start,…